The rationale for prostaglandin E1 in erectile failure: A survey of worldwide experience

Journal of Urology

Volumn 155, Issue 3, 1996, Pages 802-815

  Porst, Hartmut ^a  

^a Urological Office   (Germany)

Author keywords

impotence; penile erection; pharmacology; prostaglandins E; vasodilator agents

Indexed keywords

LINSIDOMINE; PAPAVERINE; PHENTOLAMINE; PROSTAGLANDIN E1;

CLINICAL TRIAL; CORPUS CAVERNOSUM; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FIBROSIS; HUMAN; HYPOTENSION; IMMUNE SYSTEM; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NORADRENALIN RELEASE; ORAL DRUG ADMINISTRATION; PENIS ERECTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIAPISM; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; REVIEW; SMOOTH MUSCLE RELAXATION; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME; UNITED STATES;

EID: 0030071844     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66315-8     Document Type: Review

References (219)

1. Schrör, K. and Smith, E. F., III: Dictionary of Prostaglandins. München: Medikon-Verlag, p. 39, 1990.
2. Kurzrock, R. and Lieb, C. C.: Biochemical studies of human semen II. The action of semen on human uterus. Proc. Soc. Exp. Biol. Med., 28: 268, 1930.
3. Euler, U. S.: Über die spezifische blutdrucksenkende Substanz des menschlichen Prostata- und Samenblasensekretes. Klin. Woschr., 14: 1182, 1935.
4. Bergström, S., Ryhage, R., Samuelsson, B. and Sjövall, I.: Prostaglandins and related factors. 15. The structures of prostaglandin E1, F1-alpha and F1-beta. J. Biol. Chem., 238: 3555, 1963.
5. Paoletti, R.: Biochemistry and pharmacology of prostaglandin E1: introductory remarks. In: Prostaglandin E1 in Atherosclerosis. Edited by H. Sinzinger and W. Rogatti. New York: Springer-Verlag, pp. 3-7, 1986.
6. Carlson, L. A. and Eriksson, I.: Femoral-artery infusion of prostaglandin E 1 in severe peripheral vascular disease. Lancet, 1: 155, 1973.
7. Peskar, B. A., Hesse, W. H., Rogatti, W., Diehm, C., Rudofsky, G., Schweer, H. and Seyberth, H. W.: Formation of 13,14-dihydro-prostaglandin E1 during intravenous infusions of prostaglandin E1 in patients with peripheral arterial occlusive disease. Prostaglandins, 41: 225, 1991.
8. Braun, M., Bruch, L., Ney, P., Torsello, G. and Schrör, K.: Actions of PGE1, PGE0, 15-Keto PGE1 on vessel tone in vitro. In: Prostaglandin E1. New Aspects on Pharmacology, Metabolism and Clinical Efficacy. Edited by C. Diehm, H. Sinzinger and W. Rogatti. New York: Springer-Verlag, pp. 12-20, 1991.
9. Ney, P., Braun, M., Szymanski, C., Bruch, L. and Schrör, K.: Antiplatelet, antineutrophil and vasodilating properties of 13,14-dihydro-PGE1, (PGE0) - an in vivo metabolite of PGE1 in man. Eicosanoids, 4: 177, 1991.
10. Golub, M., Zia, P., Matsuno, M. and Horton, R.: Metabolism of prostaglandins A1 and E1 in man. J. Clin. Invest., 56: 1404, 1975.
11. Roy, A. C., Adaikan, P. G., Sen, D. K. and Ratnam, S. S.: Prostaglandin 15-hydroxydehydrogenase activity in human penile corpora cavernosa and its significance in prostaglandin-mediated penile erection. Brit. J. Urol., 64: 180, 1989.
12. van Ahlen, H., Peskar, B., Sticht, G. and Hertfelder, H.-J.: Pharmacokinetics of vasoactive substances administered into the human corpus cavernosum. J. Urol., part 2, 151: 455A, abstract 909, 1994.
13. Chen, J.-K., Hwang, T. I. S. and Yang, C.-R.: Comparison of effects following the intracorporeal injection of papaverine and prostaglandin E1. Brit. J. Urol., 69: 404, 1992.
14. Abber, J. C. and Hinman, F., Jr.: Short-course papaverine injections for restoration of potency. J. Urol., part 2, 135: 364A, abstract 1039, 1986.
15. Beretta, G., Zanollo, A., Fanciullacci, F. and Catanzaro, F.: Intracavernous injection of papaverine in paraplegic males. Acta Eur. Fertil., 17: 283, 1986.
16. Strachan, J. R. and Pryor, J. P.: Diagnostic intracorporeal papaverine and erectile dysfunction. Brit. J. Urol., 59: 264, 1987.
17. Wespes, E., Delcour, C., Rondeux, C., Struyven, J. and Schulman, C. C.: The erectile angle: objective criterion to evaluate the papaverine test in impotence. J. Urol., 138: 1171, 1987.
18. Buvat, J., Lemaire, A., Marcolin, G., Dehaene, J. L. and Buvat-Herbaut, M.: Intracavernous injection of papaverine (ICIP): assessment of its diagnostic and therapeutic value in 100 impotent patients. World J. Urol., 5: 150, 1987.
19. Bahnson, R. R. and Catalona, W. J.: Papaverine testing of impotent patients following nerve-sparing radical prostatectomy. J. Urol., 139: 773, 1988.
20. Puppo, P., De Rose, A. F., Pittaluga, P. and Giuliani, L.: Diagnosis of male impotence after intracavernous papaverine test. Eur. Urol., 15: 213, 1988.
21. Radzinski, C., Herschorn, S., Abara, B. and Klotz, L.: Intracavernous injection of papaverine for erectile impotence. J. Urol., part 2, 139: 403A, abstract 959, 1988.
22. Schnyder von Wartensee, M., Sieber, A. and Studer, U. E.: Therapie der erektilen Dysfunktion mit Papaverin - 21/2 Jahre Erfahrung. Schweiz. Med. Woschr., 118: 1099, 1988.
23. Qualey, B. and Fallon, B.: Results of a self-injection program for male impotence. J. Urol., part 2, 139: 404A, abstract 964, 1988.
24. Pettirossi, O. and Serenelli, G.: Intracavernous injection of papaverine, phentolamine and phenoxybenzamine. Acta Urol. Belg., 56: 211, 1988.
25. Török, A., Szekely, J. and Götz, F.: Papaverine-induced erection. Int. Urol. Nephrol., 21: 195, 1989.
26. Darewicz, J. and Galek, L.: Priapism as a complication following diagnostic papaverine test. Z. Urol. Nephrol., 82: 317, 1989.
27. Lenk, S., Schönherr, G. and Korner, I.: Corpus cavernosum injection treatment of erectile impotence. Z. Urol. Nephrol., 83: 539, 1990.
28. Dhabuwala, C. B., Kerkar, P., Bhutwala, A., Kumar, A. and Pierce, J. M.: Intracavernous papaverine in the management of psychogenic impotence. Arch. Androl., 24: 185, 1990.
29. Lomas, G. M. and Jarow, J. P.: Risk factors for papaverine-induced priapism. J. Urol., 147: 1280, 1992.
30. Kapoor, V. K., Chahal, A. S., Jyoti, S. P., Mundkur, Y. J., Kotwal, S. V. and Mehta, V. K.: Intracavernous papaverine for impotence in spinal cord injured patients. Paraplegia, 31: 675, 1993.
31. Takahashi, Y., Takayama, S., Itou, T., Owada, K. and Omori, Y.: Effect of intracavernous injection with papaverine on diabetic impotence in Japan. Int. J. Impotence Res., suppl. 1, 6: D144, 1994.
32. Porst, H.: Komplikationen vasoaktiver Substanzen in der Diagnostik und Therapie der erektilen Dysfunktion. Urologe B, 33: 13, 1993.
33. Mahmoud, K. Z.: Experience with self-injection in Egypt. In: The Role of Alprostadil in the Diagnosis and Treatment of Erectile Dysfunction. Edited by I. Goldstein and T. F. Lue. Princeton: Excerpta Medica, Inc., pp. 131-141, 1993.
34. Bähren, W., Stief, C., Scherb, W., Gall, H., Gallwitz, A. and Altwein, J. E.: Rational diagnosis of erectile dysfunction by using a pharmacological test. Akt. Urol., 17: 177, 1986.
35. Robinette, M. A. and Moffat, M. J.: Intracorporal injection of papaverine and phentolamine in the management of impotence. Brit. J. Urol., 58: 692, 1986.
36. Bodner, D. R., Lindan, R., Leffler, E., Kursh, E. D. and Resnick, M. I.: The application of intracavernous injection of vasoactive medications for erection in men with spinal cord injury. J. Urol., 138: 310, 1987.
37. Padma-Nathan, H., Goldstein, I., Payton, T. and Krane, R. J.: Intracavernosal pharmacotherapy: the pharmacologic erection program. World J. Urol., 5: 160, 1987.
38. Nellans, R. E., Ellis, L. R. and Kramer-Levien, D.: Pharmacological erection: diagnosis and treatment applications in 69 patients. J. Urol., 138: 52, 1987.
39. Sidi, A. A., Reddy, P. K. and Chen, K. K.: Patient acceptance of and satisfaction with vasoactive intracavernous pharmacotherapy for impotence. J. Urol., 140: 293, 1988.
40. Jünemann, K. P., Jecht, E., Müller-Mattheis, V., Weiske, W. H., Wetterauer, U., Baccouche, M., Lühmann, R., Zentgraf, M., Bähren, W. and Altwein, J. E.: Open multicenter study with a drug combination of papaverine hydrochloride and phentolamine mesylate, for the differential diagnosis of erectile dysfunction. Urologe A, 27: 2, 1988.
41. Watters, G. R., Keogh, E. J., Earle, C. M., Carati, C. J., Wisniewski, Z. S., Tulloch, A. G. S. and Lord, D. J.: Experience in the management of erectile dysfunction using the intracavernosal self-injection of vasoactive drugs. J. Urol., 140: 1417, 1988.
42. Nelson, R. P.: Injections of papaverine and regitine into the corpora cavernosa for erectile dysfunction: clinical results in 60 patients. South. Med. J., 82: 26, 1989.
43. Fein, R. L.: Classification of sexual dysfunction for management of intracavernous medication-induced erections. J. Urol., 143: 298, 1990.
44. Kerfoot, W. W. and Carson, C. C.: Pharmacologically induced erections among geriatric men. J. Urol., 146: 1022, 1991.
45. Thon, W. F., Hartmann, U. and Study Group: Efficacy and safety of intracavernous self-injection with a papaverine/phentolamine mixture. Urologe A, 32: 466, 1993.
46. Ishii, N., Watanabe, H., Irisawa, C., Kikuchi, Y., Kubota, Y., Kawamura, S., Suzuki, K., Chiba, R., Tokiwa, M. and Shirai, M.: Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence. J. Urol., 141: 323, 1989.
47. Hwang, T. I.-S., Yang, C.-R., Wang, S.-J., Chang, C.-L., Tzai, T.-S., Chang, C.-H. and Wu, H.-C.: Impotence evaluated by the use of prostaglandin E1. J. Urol., 141: 1357, 1989.
48. Mori, K., Tanda, H., Kato, S., Ohnishi, S., Nakajima, H., Ujiie, T., Aoki, M., Yamaguchi, Y. and Kumamoto, Y.: Clinical assessments of the spontaneous erection due to the repeat intracavernous injection of prostaglandin E1 in the treatment of impotence. Int. J. Impotence Res., 1: 252, 1989.
49. Block, T., Schneider, B., Theiss, M. and Zink, R. A.: Alternative Behandlungsweise bei der Präparatermittlung und Dosisfindung zur Therapie der erektilen Dysfunktion. Urologe A, suppl., 38: A66, P158, 1989.
50. Mattarelli, G. and Leibundgut, B.: Prostaglandin E1 one-way syringes for routine diagnostic of erectile dysfunction. Int. J. Impotence Res., suppl. 2, 2: 220, 1990.
51. Earle, C. M., Keogh, E. J., Wisniewski, Z. S., Tulloch, A. G. S., Lord, D. J., Watters, G. R. and Glatthaar, C.: Prostaglandin E1 therapy for impotence, comparison with papaverine. J. Urol., 143: 57, 1990.
52. Ravnik-Oblak, M., Oblak, C., Vodusek, D. B., Kristl, V. and Ziherl, S.: Intracavernous injection of prostaglandin E1 in impotent diabetic men. Int. J. Impotence Res., 2: 143, 1990.
53. Schramek, P., Dorninger, R., Waldhauser, M., Konecny, P. and Porpaczy, P.: Prostaglandin E1 in erectile dysfunction. Efficiency and incidence of priapism. Brit. J. Urol., 65: 68, 1990.
54. Buvat, J., Buvat-Herbaut, M., Lemaire, A., Marcolin, G. and Dehaene, J. L.: Diagnostic value of intracavernous injections of 20 μg of prostaglandin E1 in impotence. Int. J. Impotence Res., 3: 105, 1991.
55. Gerber, G. S. and Levine, L. A.: Pharmacological erection program using prostaglandin E1. J. Urol., 146: 786, 1991.
56. Beretta, G., Zanollo, A. and Portalupi, W.: Intracavernous injections of prostaglandin E1 in the treatment of erectile dysfunctions. Arch. Ital. Urol., 52: 481, 1991.
57. Bellorofonte, C., Ruoppolo, M., Dell Ácqua, S., Zaatar, C., Ferri, P. M. and Yamak, R.: Intracavernous drug infusion: considerations on studies performed in the past decade and new findings involving PGE1. Arch. Ital. Urol., 63: 475, 1991.
58. Ishigooka, M., Irisawa, C., Watanabe, H., Adachi, M., Ishii, N. and Nakada, T.: Intracavernous injection of prostaglandin E1: the application to cavernosography and penile blood flow measurement for the diagnosis of venogenic impotence. Urol. Int., 46: 193, 1991.
59. Adaikan, P. G., Ng, S. C., Chan, C. L. K., Kumar, J., Biswas, A., Marshall, B. and Ratnam, S. S.: Seven years experience with PGE1 in the treatment of erectile failure. Int. J. Impotence Res., suppl. 2, 4: 107, 1992.
60. Calabro, A., Pescatori, E. S., Marin, A., Atribani, W. and Pagano, F.: Intracavernous self-injection of prostaglandin E1 as treatment for impotence in the elderly. Int. J. Impotence Res., suppl. 2, 4: 110, 1992.
61. Donatucci, C. F. and Lue, T. F.: The combined intracavernous injection and stimulation test: diagnostic accuracy. J. Urol., 148: 61, 1992.
62. Stackl, W.: Experience with auto-injection in Austria. In: The Role of Alprostadil in the Diagnosis and Treatment of Erectile Dysfunction. Edited by I. Goldstein and T. F. Lue. Princeton: Excerpta Medica, Inc., pp. 127-130, 1993.
63. Araki, T., Fujimoto, H., Yamanaka, M., Kunitomi, K. and Takamoto, H.: Evaluation of the influence of anxiety on prostaglandin E1-test. Int. J. Impotence Res., suppl. 1, 6: D46, 1994.
64. Sogari, P. R., Da Ros, C. T., Telöken, C., Bolassel, C. and Souto, C. A. V.: Comparison of papaverine hydrochloride versus prostaglandin E1 in pharmacological erection test. Int. J. Impotence Res., suppl. 1, 6: D110, 1994.
65. Wang, C. J., Wu, C. C., Huang, C. H. and Chiang, C. P.: A comparative study with intracavernous injection of prostaglandin E1 versus papaverine for the diagnostic assessment of erectile impotence. Int. J. Impotence Res., suppl. 1, 6: D146, 1994.
66. Oblak, C. and Ravnik-Oblak, M.: Effect of prostaglandin E1-test in relation to the cause of impotence in diabetic patients. Int. J. Impotence Res., suppl. 1, 6: P43, 1994.
67. Wu, C. J., Xue, Z. Y., Kongkanand, A. and Adaikan, P. G.: Safety and efficacy dose-response study in patients with erectile dysfunction using the lowest optimal dose of CAVERJECT™ in office versus at-home settings. Int. J. Impotence Res., suppl. 1, 6: P45, 1994.
68. Gana, T. and Quiznos, L. F.: Safety and efficacy dose-response study in patients with erectile dysfunction using various dosages of CAVERJECT™. Int. J. Impotence Res., suppl. 1, 6: P46, 1994.
69. Porst, H.: Ten years of experience with various vasoactive drugs. Comparative studies in over 4000 patients. Int. J. Impotence Res., suppl. 1, 6: D149, 1994.
70. Weiske, W. H.: Personal communication, 1994.
71. Lumley, P., Humphrey, P. P., Kennedy, J. and Coleman, R. A.: Comparison of the potencies of some prostaglandins as vasodilators in three vascular beds of the anaesthetised dog. Eur. J. Pharmacol., 81: 421, 1982.
72. Kawasaki, A., Ishii, K., Kitagawa, T., Sakata, M., Ishii, M. and Ojima, M.: Effect of prostaglandin E1-cyclodextrin clathrate compound (PGE1-alpha CD) on the experimental model of acute arterial obstruction. Relating to its vasodilator and antiplatelet aggregation actions. Oyo Yakuri, 17: 1043, 1971.
73. Schrör, K. and Smith, E. F., III: Dictionary of Prostaglandins. München: Medikon-Verlag, p. 100, 1990.
74. Rudofsky, G.: Zur Wirkung von Prostaglandin E1 auf Kollateralarterien bei arterieller Verschusskrankheit. In: Prostaglandin E1. Wirkungen und Therapeutische Wirksamkeit. Edited by H. Heidrich, H. Böhme and W. Rogatti. New York: Springer-Verlag, pp. 144-150, 1988.
75. Ziehe, M., Morbidelli, L., Parenti, A. and Ledda, F.: Nitric oxide modulates angiogenesis elicited by prostaglandin E1 in rabbit cornea. In: Abstract Book 9th International Conference on Prostaglandins and Related Compounds. June 6-10, 1994. Florence, Italy, p. 11, 1994.
76. Krone, W., Klass, A., Nägele, H. and Behnke, B.: Effects of prostaglandin E1 on low density lipoprotein receptor activity and cholesterol synthesis in freshly isolated human leucocytes. In: Prostaglandin E1 in Atherosclerosis. Edited by H. Sinzinger and W. Rogatti. New York: Springer-Verlag, pp. 32-38, 1986.
77. Lupatteli, G., Virgolini, J., O'Grady, I. and Sinzinger, H.: PGE1 decreases the LDL-entry into rabbit arterial wall in vivo. In: Abstract Book 7th International Conference on Prostaglandins and Related Compounds. May 28-June 1, 1990. Florence, Italy, p. 61, 1990.
78. Sinzinger, H.: Inhibition of mitotic and proliferative activity of smooth muscle cells by prostaglandin E1. In: Prostaglandin E1 in Atherosclerosis. Edited by H. Sinzinger and W. Rogatti. New York: Springer-Verlag, pp. 39-48, 1986.
79. Weeks, J. R., Sekhar, N. C. and Ducharme, D. W.: Relative activity of prostaglandins E1, A1, E2 and A2 on lipolysis, platelet aggregation, smooth muscle and the cardiovascular system. J. Pharm. Pharmacol., 21: 103, 1969.
80. Rexroth, W., Amendt, K., Römmele, U., Stein, U., Wagner, E. and Hild, R.: Effekte von PGE1 auf Hämodynamik und Extremitätenstoffwechsel bei Gesunden und Patienten mit arterieller Verschlusskrankheit Stadium III u. IV. VASA, 14: 220, 1985.
81. Rudofsky, G.: The effect of intraarterial and intravenous prostaglandin E1 in a model of ischemia in healthy volunteers. In: Prostaglandin E1 in Atherosclerosis. Edited by H. Sinzinger and W. Rogatti. New York: Springer-Verlag, pp. 49-53, 1986.
82. Hach, W., Zanke, B. W., Sauerwein, G. and Özen, Y.: Treatment of stage II b peripheral arterial occlusive disease with short-term intraarterial infusions of prostaglandin E1. In: Prostaglandin E1 in Atherosclerosis. Edited by H. Sinzinger and W. Rogatti. New York: Springer-Verlag, pp. 66-74, 1986.
83. Blume, J., Rühlmann, K. U. and Kiesewetter, H.: Clinical efficacy of intraarterial PGE1-infusion in intermittent claudication. In: Prostaglandin E1 in Atherosclerosis. Edited by H. Sinzinger and W. Rogatti. New York: Springer-Verlag, pp. 75-80, 1986.
84. Bruch, H.-P., Hörl, M. and Herold, A.: Prostaglandin E1 in arterial occlusive disease in stages III and IV according to Fontaine. In: Prostaglandin E1 in Atherosclerosis. Edited by H. Sinzinger and W. Rogatti. New York: Springer-Verlag, pp. 81-91, 1986.
85. Heidrich, H., Dimroth, H., Gutman, M., Helmis, I., Peters, A. and Ranft, I.: Long-term intravenous infusion of PGE1 in peripheral arterial blood flow disorders: results of an open screening study with patients in Fontaine's stages III and IV. In: Prostaglandin E1 in Atherosclerosis. Edited by H. Sinzinger and W. Rogatti. New York: Springer-Verlag, pp. 92-98, 1986.
86. Pillay, D. J., Karmazyn, M. and Pope, B. L.: Activation of suppressor cells by low molecular weight factors secreted by spleen cells of tumor-bearing mice: modulatory role of prostaglandins. Int. J. Immunopharmacol., 8: 227, 1986.
87. O'Flaherty, J. T., Kreutzer, D. L. and Ward, P. A.: Effect of prostaglandin E1, E2 and F2 alpha on neutrophil aggregation. Prostaglandins, 17: 201, 1979.
88. Kury, P. G., Ramwell, P. W. and McConnell, H. M.: The effect of prostaglandins E1 and E2 on the human erythrocyte as monitored by spin labels. Biochem. Biophysical. Res. Comm., 56: 478, 1974.
89. Yamaguchi, H., Ishimura, S., Hakoshima, A., Furukawa, K. and Takahashi, M.: Therapeutic study of reduced red cell deformability in peripheral vascular disease. In: 3. Deutsch-Japanischer Kongress für Angiologie. Gräfelfing: Demeter-Verlag, p. 342, 1985.
90. Ney, P., Braun, M., Szymanski, C. and Schrör, K.: 13,14-dihydro-PGE1 (PGE0) but not 15-Keto-PGE1 is a potent inhibitor of human platelet and neutrophil activation. In: Prostaglandin E1. New Aspects on Pharmacology. Metabolism and Clinical Efficacy. Edited by C. Diehm, H. Sinzinger and W. Rogatti. New York: Springer-Verlag, pp. 21-32, 1991.
91. Breddin, H. K. and Weichert, W.: Effects of prostaglandins on platelet function ex vivo and in animal thrombosis models. In: Prostaglandin E1 in Atherosclerosis. Edited by H. Sinzinger and W. Rogatti. New York: Springer-Verlag, pp. 13-21, 1986.
92. Sinzinger, H., Fitscha, P., Grady, I. O., Rauscha, F. and Rogatti, W.: Prostaglandin E1 and nitric oxide donors synergize inducing thromboresistance. In: Abstract Book 7th International Conference on Prostaglandins and Related Compounds. May 28-June 1, 1990, Florence, Italy, p. 291, 1990.
93. Moltz, H.: E-series prostaglandins and arginine vasopressin in the modulation of male sexual behavior. Neurosci. Biobehavioral Rev., 14: 109, 1990.
94. Manka, M. S. and Horrobin, D. F.: Prostaglandin (PG) precursors in diabetic neuropathy and the effects of treatment with PG precursors on nerve function. In: Abstract Book, 7th International Conference on Prostaglandins and Related Compounds. May 28-June 1, 1990. Florence, Italy, p. 350, 1990.
95. Omawari, W., Ryo, S., Yokoyama, M., Wakitani, K., Sawada, M., Okegawa, T. and Kawasaki, A.: Preventive effects of PGE1 - analogue OP 1206 on neuropathy and endothelial damage in streptozotocin-diabetic rats. In: Abstract Book, 7th International Conference on Prostaglandins and Related Compounds. May 28-June 1, 1990. Florence, Italy, p. 351, 1990.
96. Johnston, H. H., Herzog, J. P. and Lauler, D. P.: Effect of prostaglandin E1 on renal hemodynamics, sodium and water excretion. Amer. J. Physiol., 213: 939, 1967.
97. Abrams, P. H. and Feneley, R. C.: The actions of prostaglandins on the smooth muscle of the human urinary tract in vitro. Brit. J. Urol., 47: 909, 1975.
98. Boyarsky, S., Labay, P. and Gerber, C.: Prostaglandin inhibition of ureteral peristalsis. Invest. Urol., 4: 9, 1966.
99. Lundstam, S., Jonsson, O., Kihl, B. and Pettersson, S.: Prostaglandin synthetase inhibition of renal pelvic smooth muscle in the rabbit. Brit. J. Urol., 57: 390, 1985.
100. Forman, A., Andersson, K. E., Henriksson, L., Rud, T. and Ulmsen, U.: Effects of nifedipine on the smooth muscle of the human urinary tract in vitro and in vivo. Acta Pharmacol. Toxicol., 43: 111, 1978.
101. Domschke, W., Domschke, S., Hornig, D. and Demling, L.: Prostaglandin-stimulated gastric mucus secretion in man. Acta Hepatogastroenterol., 25: 292, 1978.
102. Way, L. and Durbin, R. P.: Inhibition of gastric acid secretion in vitro by prostaglandin E1. Nature, 221: 874, 1969.
103. Pharmaprofil: Misoprostol. Klinikarzt, 16: 121, 1987.
104. Adaikan, P. G.: Pharmacology of human penis. M. Sc. Thesis. University of Singapore, p. 213, 1979.
105. Adaikan, P. G., Karim, S. M., Kottegoda, S. R. and Ratnam, S. S.: Cholinoceptors in the corpus cavernosum of the human penis. J. Auton. Pharmacol., 3: 107, 1983.
106. Hedlund, H. and Andersson, K.-E.: Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery. J. Urol., 134: 1245, 1985.
107. Hedlund, H., Andersson, K.-E., Fovaeus, M., Homlquist, F. and Uski, T.: Characterization of contraction-mediating prostanoid receptors in human penile erectile tissues. J. Urol., 141: 182, 1989.
108. Kim, S. C., Lee, S. H., Cha, Y. C. and Kim, K. D.: Prostacycline/ thromboxane A2 ratio in arteriogenic impotence. Int. J. Impotence Res., 1: 238, 1989.
109. Bosch, R. J. L. H., Benard, F., Aboseif, S. R., Stief, C. G., Stackl, W., Lue, T. F. and Tanagho, E. A.: Changes in penile hemodynamics after intracavernous injection of prostaglandin E1 and prostaglandin I2 in pigtailed monkeys. Int. J. Impotence Res., 1: 211, 1989.
110. Jeremy, J. Y., Morgan, R. J., Mikhailidis, D. P. and Dandona, P.: Prostacyclin synthesis by the corpora cavernosa of the human penis: evidence for muscarinic control and pathological implications. Prostaglandins Leukotrienes Med., 23: 211, 1986.
111. Saenz de Tejada, I., Carson, M. P., Taylor, L., Polgar, P. and Goldstein, I.: Prostaglandin production by human corpus cavernosum endothelial cells (HCC EC) in culture. J. Urol., part 2, 139: 252A, abstract 358, 1988.
112. Melman, A., Maayani, S. and Schwartzman, M.: Prostaglandin synthesis as a putative biochemical correlate of spontaneous myotonic oscillations in the isolated human penile erectile tissue. J. Urol., part 2, 135: 361A, abstract 1028, 1986.
113. Roy, A. C., Tan, S. M., Kottegoda, S. R. and Ratnam, S. S.: Ability of human corpora cavernosa muscle to generate prostaglandins and thromboxanes in vitro. IRCS Med. Sci., 12: 608, 1984.
114. Levin, R. M., Tong, Y.-C., Hypolite, J. A. and Broderick, G.: Correlation of calcium movements with the contractile response of the rabbit corpus cavernosum using FURA-2 calcium fluorescence. Int. J. Impotence Res., 3: 141, 1991.
115. Eckert, R. E., Zaubitzer, T., Derouet, H. and Ziegler, M.: Intracellular control of cavernous smooth muscle contractility. J. Urol., part 2, 151: 431A, abstract 814, 1994.
116. Bergström, S., Farnebo, L. O. and Fuxe, K.: Effect of prostaglandin E 2 on central and peripheral catecholamine neurons. Eur. J. Pharmacol., 21: 362, 1973.
117. Rump, L. C. and Schollmeyer, P.: Effects of endogenous and synthetic prostanoids, the thromboxan A2 receptor agonist U-46619 and arachidonic acid on [3H]-noradrenaline release and vascular tone in rat isolated kidney. Brit. J. Pharmacol., 97: 819, 1989.
118. Andersson, K. E. and Holmquist, F.: Mechanisms for contraction and relaxation of human penile smooth muscle. Int. J. Impotence Res., 2: 209, 1990.
119. Saenz de Tejada, I., Kim, N., Lagan, I., Krane, R. J. and Goldstein, I.: Regulation of adrenergic activity in penile corpus cavernosum. J. Urol., 142: 1117, 1989.
120. 1 adrenergic receptor subtype mRNA expression in human corpus cavernosum. J. Urol., part 2, 149: 285A, abstract 287, 1993.
121. Molderings, G. J., Göthert, M., Van Ahlen, H. and Porst, H.: Noradrenaline release in human corpus cavernosum and its modulation via presynaptic alpha 2-adrenoceptors. Fundam. Clin. Pharmacol., 3: 497, 1989.
122. Molderings, G. J., van Ahlen, H. and Göthert, M.: Modulation of noradrenaline release in human corpus cavernosum by presynaptic prostaglandin receptors. Int. J. Impotence Res., 4: 19, 1992.
123. Italiano, G., Calabro, A., Pescatori, E. S., Marin, A. and Pagano, F.: Profile of action of prostaglandin E1 (PGE1) in the isolated rabbit erectile tissue. Pre- and postjunctional effects. Int. J. Impotence Res., suppl. 1, 6: A22, 1994.
124. Daley, J. T., Brown, M. L., Farber, H. and Saenz de Tejada, I.: Prostaglandin production during hypoxia in rabbit corpus cavernosum. J. Urol., part 2, 149: 285A, abstract 288, 1993.
125. Saenz de Tejada, I. and Moreland, R. B.: Physiology of erection, pathophysiology of impotence and implications of PGE1 in the control of collagen synthesis in the corpus cavernosum. In: The Role of Alprostadil in the Diagnosis and Treatment of Erectile Dysfunction. Edited by I. Goldstein and T. F. Lue. Princeton: Excerpta Medica, Inc., pp. 3-16, 1993.
126. Moreland, R. B., Traish, A., McMillin, M. A., Smith, B., Goldstein, I. and Saenz de Tejada, I.: PGE1 suppresses the induction of new collagen synthesis by transforming growth factor β1 in human corpus cavernosum smooth muscle: mechanism of penile ischemia associated fibrosis. J. Urol., part 2, 151: 431A, abstract 815, 1994.
127. Telöken, C., Lisboa, J. F., Thorel, E., Rössler, R. L. and Souto, C. A. V.: Side effects of intracorporeal papaverine injection in the management of impotence: evaluation at 30 months of follow up. J. Urol., part 2, 139: 405A, abstract 966, 1988.
128. Ruutu, M., Lindström, B. L., Virtanen, J. and Alfthan, O.: Intracavernous self-injection for erectile failure. Eur. Urol., 15: 96, 1988.
129. Kirkeby, H. J., Petersen, T. and Poulsen, E. U.: Pharmacologically induced erection in patients with multiple sclerosis. Scand. J. Urol. Nephrol., 22: 241, 1988.
130. Herschorn, S. and Abara, E.: Follow-up of self administered intracorporeal papaverine. J. Urol., part 2, 141: 221A, abstract 205, 1989.
131. Tullii, R. E., Degni, M. and Pinto, A. F. C.: Fibrosis of the cavernous bodies following intracavernous auto-injection of vasoactive drugs. Int. J. Impotence Res., 1: 49, 1989.
132. Bouilly, P., Daniel, C. and Lefebvre-Vilardebo, M.: Intracavernous self-injections: pleading for a careful selection of patients - about 62 patients with a minimal 3 years follow-up. Int. J. Impotence Res., suppl. 2, 2: 273, 1990.
133. Buvat, J., Buvat-Herbaut, M., Lemaire, A. and Marcolin, G.: Reduced rate of fibrotic nodules in the cavernous bodies following auto-intracavernous injections of moxisylyte compared to papaverine. Int. J. Impotence Res., 3: 123, 1991.
134. Cooper, A. J.: Evaluation of I-C papaverine in patients with psychogenic and organic impotence. Canad. J. Psychiatry, 36: 574, 1991.
135. Weidner, W., Schröder-Printzen, I., Fischer, C., Rudnick, J., Altinkilic, B. and Brähler, E.: Experience in the treatment of erectile dysfunction using the intracavernosal self-injection of papaverine: results of a prospective study after a median follow-up of 42 months involving 135 patients and 10766 injections. World J. Urol., 10: 179, 1992.
136. Sieber, A., Schnyder von Wartensee, M., Thönen, H. J. and Studer, U. E.: Intracavernous self-injection in impotence. Ther. Umsch., 49: 49, 1992.
137. Al-Juburi, A. and O'Donnell, P. D.: Penile self injection for impotence. J. Urol., part 2, 139: 405A, abstract 968, 1988.
138. Girdley, F. M., Bruskewitz, R. C., Feyzi, J., Graversen, P. H. and Gasser, T. C.: Intracavernous self-injection for impotence: a long-term therapeutic option? Experience in 78 patients. J. Urol., 140: 972, 1988.
139. Nachtsheim, D. and Walther, P. C.: Treatment of impotence with pharmacologic injections. J. Urol., part 2, 139: 403A, abstract 960, 1988.
140. Levine, S. B., Althof, S. E., Turner, L. A., Risen, C. B., Bodner, D. R., Kursh, E. D. and Resnick, M. I.: Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J. Urol., 141: 54, 1989.
141. Broderick, G. A., Switters, D., Stone, A. R. and deVere White, R. W.: Papaverine/phentolamine: the efficacy and safety of low dosage long-term therapy. J. Urol., part 2, 143: 304A, abstract 462, 1990.
142. Dinsmore, W. W.: Medical treatment of impotence with papaverine and phentolamine intracavernosal injection. Ulster Med. J., 59: 174, 1990.
143. Lakin, M. M., Montague, D. K., Medendorp, S. V., Tesar, L. and Schover, L. R.: Intracavernous injection therapy: analysis of results and complications. J. Urol., 143: 1138, 1990.
144. Althof, S. E., Turner, L. A., Levine, S. B., Risen, C., Kursh, E., Bodner, D. and Resnick, M.: Why do so many people drop out from auto-injection therapy for impotence? J. Sex Marital Ther., 15: 121, 1989.
145. Van Driel, M. F., Mooibroek, J. J., van de Wiel, H. B. M. and Mensink, H. J. A.: Intracavernous pharmacotherapy: psychological, sexological and medical aspects. Int. J. Impotence Res., 3: 95, 1991.
146. Derouet, H., Caspari, D., Münch, M. and Ziegler, M.: Acceptance of corpus cavernosum self-injection therapy in long-term treatment of erectile dysfunction. Urologe A, 30: 423, 1991.
147. Witjes, W. P. J., Meuleman, E. J. H., Lycklama à Nijeholt, G. A. B., van Driel, M. F., Leliefeld, H. H. J., Kropman, R. F. and Doesburg, W. H.: The efficacy and acceptance of intracavernous autoinjection therapy with the combination of papaverine/phentolamine. Int. J. Impotence Res., 4: 65, 1992.
148. Chan, J. C. K., Levenson, S., Payton, T. R., Krane, R. J. and Goldstein, I.: Five to seven year follow-up of patients in a pharmacologic erection program: satisfaction and complications. J. Urol., part 2, 147: 309A, abstract 387, 1992.
149. Gall, H., Sparwasser, C., Bähren, W., Scherb, W., Holzki, G. and Irion, R.: Long-term results of corpus cavernosum auto-injection therapy for chronic erectile dysfunction. Urologe A, 31: 31, 1992.
150. Porst, H., van Ahlen, H., Block, T., Halbig, W., Hautmann, R., Löchner-Ernst, D., Rudnick, J., Staehler, G., Weber, H. M., Weidner, W. and Weiske, W. H.: Intracavernous self-injection of prostaglandin E1 in the therapy of erectile dysfunction. Vasa, suppl., 28: 50, 1989.
151. Bucher, A., Mrstik, C. and Stögermayer, F.: Therapeutic effect of PGE1 in the treatment of erectile dysfunction. Akt. Urol., 21: 17, 1990.
152. Weiske, W. H.: Prostaglandin E1 (PGE1) in diagnosis and treatment of erectile dysfunction. Int. J. Impotence Res., suppl. 2, 2: 234, 1990.
153. Sister, M. P.: Prostaglandin E1 in erectile dysfunction: 20 months of experience with 483 patients in a self-injection program. Int. J. Impotence Res., suppl. 2, 2: 287, 1990.
154. Weiske, W. H.: Long-term results in self-injection therapy (SIT) with PGE1 in 220 patients. Int. J. Impotence Res., suppl. 2, 4: A87, 1992.
155. Lakin, M. M., Montague, D. K., Schover, L. R., Chen, R. N. and Ignaut, C. A.: Fibrosis with intracavernous injection therapy utilizing prostaglandin-E1 (PGE-1). J. Urol., part 2, 147: 309A, abstract 385, 1992.
156. Daley, J., McMahon, C. G., Stricker, P. and Lowy, M.: Comparison of prostaglandin E1 and papaverine self injection program drop out rates. Int. J. Impotence Res., suppl. 1, 6: D 86, 1994.
157. Porst, H.: Experience with alprostadil in diagnosis and therapy in Germany. In: The Role of Alprostadil in the Diagnosis and Treatment of Erectile Dysfunction. Edited by I. Goldstein and T. F. Lue. Princeton: Excerpta Medica, Inc., pp. 142-154, 1993.
158. Aboseif, S. R., Breza, J., Bosch, R. J. L. H., Benard, F., Stief, C. G., Stackl, W., Lue, T. F. and Tanagho, E. A.: Local and systemic effects of chronic intracavernous injection of papaverine, prostaglandin E1 and saline in primates. J. Urol., 142: 403, 1989.
159. Stackl, W., Loupal, G. and Holzmann, A.: Intracavernous injection of vasoactive drugs in the rabbit. Urol. Res., 16: 455, 1988.
160. Hwang, T. I. S., Yang, C. R., Wang, S. I., Chang, C. C., Tzai, T. S., Chang, C. H. and Wu, H. C.: Impotence evaluated by the use of prostaglandin E1. Read at Prostaglandin E1 Symposium, Taipei, Republic of China, December 16, 1989.
161. Knispel, H. H., Goessl, C. and Beckmann, R.: Effects of papaverine and prostaglandin E1 on corpus cavernosum smooth muscle of normal, vascular and diabetic impotent men. Int. J. Impotence Res., suppl. 2, 4: A10, 1992.
162. Kerfoot, W. W., Schwartz, L. B., Hagen, P.-O., Park, H. Y. and Carson, C. C.: Characterization of contracting and relaxing agents in rabbit corpus cavernosum. Surg. Forum, 42: 686, 1991.
163. Tamura, M., Hashine, K., Kimura, K., Kawanishi, Y. and Imagawa, A.: Comparison of the effect of papaverine hydrochloride and prostaglandin E1 on human corpus cavernosum. Int. J. Impotence Res., suppl. 1, 2: 141, 1990.
164. Adaikan, P. G., Lau, L. C., Singh, G., Susheela, K., Vasatha, K. and Ratnam, S. S.: Long-term intracavernous injection of papaverine and saline are detrimental to the primate cavernosum as compared to PGE1-pharmacological and histological evidences. Int. J. Impotence Res., suppl. 2, 2: 327, 1990.
165. Van Ahlen, H., Piechota, H.-J., Hermanns, M. and Krüger, E.: Metabolic changes in the human corpus cavernosum under vasoactive substances. Int. J. Impotence Res., suppl. 2, 2: 244, 1990.
166. Seidmon, E. J. and Samaha, A. M., Jr.: The pH-analysis of papaverine-phentolamine and prostaglandin E1 for pharmacologiec erection. J. Urol., 141: 1458, 1989.
167. Stackl, W., Stief, C. G., Benard, F., Aboseif, S. R., Bosch, R. J. L. H., Loupal, G., Lue, T. F. and Tanagho, E. A.: Intracavernous injection of solutions with different osmolarity and pH in the rabbit. Int. J. Impotence Res., 1: 197, 1989.
168. Gludovacz, D., Virgolini, J., Porst, H., Friehe, H., Rogatti, W. and Sinzinger, H.: PGE1-receptor identification in human and rhesus monkey corpus cavernosum cell fractions. In: Abstract Book, 7th International Conference on Prostaglandins and Related Compounds. May 28-June 1, 1990. Florence, Italy, p. 24, 1990.
169. 1 receptors in the cavernous tissue of humans, primates and canines. J. Urol., part 2, 145: 230A, abstract 70, 1991.
170. Adaikan, P. G., Kottegoda, S. R. and Ratnam, S. S.: A possible role for prostaglandin E1 in human penile erection. In: Abstract Book Second World Meeting on Impotence. Prague, Czechoslovakia, February 6, 1986.
171. Ishii, N., Watanabe, H., Irisawa, C. and Kikuchi, Y.: Therapeutic trial with prostaglandin E1 for organic impotence. In: Abstract Book Second World Meeting on Impotence. Prague, Czechoslovakia, February 2, 1986.
172. Stackl, W., Hasun, R. and Marberger, M.: Intracavernous injection of prostaglandin E1 in impotent men. J. Urol., 140: 66, 1988.
173. Porst, H.: Comparative usefulness of prostaglandin E1, papaverine and papaverine/phentolamine for the diagnosis of erectile dysfunction in 61 patients. Urologe A, 27: 22, 1988.
174. Ng, P. E. P., Tan, H. M. and Anis, M.: The use of intracorporeal self-injection of prostaglandin E1 in Malaysian men. Int. J. Impotence Res., suppl. 1, 6: D105, 1994.
175. Linet, O.: PGE1 toxicology, safety and efficacy. Read at International Symposium on Basic and Clinical Pharmacology of Penile Smooth Muscle. Madrid, Spain, December 2-3, 1994.
176. Porst, H., Buvat, J., Hauri, D., Krotovsky, G. S., Meuleman, E. J. H., Michal, V., Wagner, G. and Wespes, E.: Self-injection therapy with prostaglandin E1: long-term results of an international multicenter study according to the GCP-standard. Int. J. Impotence Res., suppl. 1, 6: D108, 1994.
177. von Heyden, B., Donatucci, C. F., Marshall, G. A., Brock, G. B. and Lue, T. F.: A prostaglandin E1 dose-response study in man. J. Urol., 150: 1825, 1993.
178. Keogh, E. J., Earle, C. M., Chew, K. K., Carr, I. L., Lee, J. L., Beck, N. G. and Burgess, T. R.: Experience with self-injection in Australia. In: The Role of Alprostadil in the Diagnosis and Treatment of Erectile Dysfunction. Edited by I. Goldstein and T. F. Lue. Princeton: Excerpta Medica, Inc., pp. 155-166, 1993.
179. Goldstein, I., Borges, F. D., Fitch, W. P., Kaufman, J., Damron, K., Moreno, J., Payton, T., Yingst, J. and Krane, R. J.: Rescuing the failed papaverine/phentolamine erection: a proposed synergistic action of papaverine, phentolamine and prostaglandin E1. J. Urol., part 2, 143: 304A, abstract 463, 1990.
180. Padma-Nathan, H.: The efficacy and synergy of polypharmaceutical intracavernosal pharmacotherapy. J. Urol., part 2, 143: 304A, abstract 464, 1990.
181. Bennett, A. H., Carpenter, A. J. and Barada, J. H.: An improved vasoactive drug combination for a pharmacological erection program. J. Urol., 146: 1564, 1991.
182. Dilworth, J. P. and Lewis, R. W.: The use of multicomponent pharmaceutical injection agents in the diagnosis and treatment of impotence. J. Urol., part 2, 145: 232A, abstract 78, 1991.
183. Allen, R. P., Engel, R. M., Smolev, J. K. and Brendler, C. B.: Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1. J. Urol., 148: 1181, 1992.
184. Collins, J. and Thijssen, A.: Experience with intracorporal prostaglandin E1, papaverine and phentolamine in patients with erectile dysfunction. J. Urol., part 2, 149: 345A, abstract 528, 1993.
185. Sweetser, P. M., Ravalli, R., Brettschneider, N. and Badlani, G.: A subjective comparison between the use of trimix, a combined 3-drug pharmacotherapy for impotence, and the use of papaverine/regitine or prostaglandin E1 in 31 patients. J. Urol., part 2, 149: 344A, abstract 527, 1993.
186. von Heyden, B., Donatucci, C. F., Kaula, N. and Lue, T. F.: Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose. J. Urol., part 2, 149: 1288, 1993.
187. McMahon, C. G.: A comparison of the response to the intracavernosal injection of a combination of all three agents in the management of impotence. Int. J. Impotence Res., 3: 113, 1991.
188. Montorsi, F., Guazzoni, G., Bergamaschi, F., Ferini-Strambi, L., Barbieri, L. and Rigatti, P.: Four-drug intracavernous therapy for impotence due to corporeal veno-occlusive dysfunction. J. Urol., part 2, 149: 1291, 1993.
189. Djamilian, M., Stief, C. G., Kuczyk, M. and Jonas, U.: Followup results of a combination of calcitonin gene-related peptide and prostaglandin E1 in the treatment of erectile dysfunction. J. Urol., part 2, 149: 1296, 1993.
190. Schwarzer, U. J., Hofman, R., Pickl, U. and Hartung, R.: Calcitonin-gene-related peptide for therapy of erectile impotence. Int. J. Impotence Res., 4: 219, 1992.
191. Kawanishi, Y., Kimura, K., Iriguchi, H., Miyamoto, T., Tamura, M., Numata, A., Yuasa, M. and Kagawa, S.: Double-blind trial of oral prostaglandin E1 on impotence. Jap. J. Urol., 83: 1655, 1992.
192. Sato, Y., Adachi, H., Suzuki, N., Horita, H., Wada, H., Shibuya, A. and Kumamota, Y.: Oral administration of prostaglandin E1 for the treatment of erectile dysfunction. Int. J. Impotence Res., suppl. 1, 6: D79, 1994.
193. Padma-Nathan, H., Keller, T., Poppit, R., Lue, T. F., Tam, P. and Place, V.: Hemodynamic effects of intraurethral alprostadil: the mediated urethral system for erection (MUSE). J. Urol., part 2, 151: 345A, abstract 469, 1994.
194. 1 bei ED. Urologe A, 34: 46, 1995.
195. Rivas, D. A., Chancellor, M. B., Erhard, M. J., Huang, B., Hirsch, I. H. and Salzman, S. K.: Comparison of erectile response to intraurethral, topical, and intracorporal pharmacotherapy in the rat model of spinal cord injury. J. Urol., part 2, 151: 495A, abstract 1071, 1994.
196. Canning, J. R. and Marchese, K. R.: Prostaglandin E1 as a topical agent for treatment of erectile dysfunction. Int. J. Impotence Res., suppl. 1, 6: D82, 1994.
197. Hepp, W., von Bary, D., Corovic, D., Diehm, C., Mühe, E., Rudofsky, G., Scheffler, P., Trübestein, G. and Vogelpohl, M.: Therapeutic efficacy of intravenous prostaglandin E1 versus pentoxifylline in patients with intermittent claudication. In: Prostaglandin E1. New Aspects on Pharmacology, Metabolism and Clinical Efficacy. Edited by D. Diehm, H. Sinzinger and W. Rogatti. New York: Springer-Verlag, pp. 101-108, 1991.
198. Heidrich, H., Ranft, J., Peters, A. and Rummel, S.: Intravenöse Prostavasin-Therapie bei peripher arteriellen Durchblutungsstörungen im Fontaine-Stadium III and IV. Früh- und Spätergebnisse einer Screening-Studie. In: Prostaglandin E1. Wirkungen und Therapeutische Wirksamkeit. Edited by H. Heidrich, H. Böhme and W. Rogatti. New York: Springer-Verlag, pp. 112-117, 1988.
199. Böhme, H., Brülisauer, M., Härtel, U. and Bollinger, A.: Kontrollierte Zweizentren-Studie zur Wirksamkeit von intraarteriellen Prostaglandin E1-Infusionen bei peripherer arterieller Verschlusskrankheit im Stadium III and IV. In: Prostaglandin E1. Wirkungen und Therapeutische Wirksamkeit. Edited by H. Heidrich, H. Böhme and W. Rogatti. New York: Springer-Verlag, pp. 118-123, 1988.
200. Trübestein, G., Diehm, C., Gruss, J. D. and Horsch, S.: Prostaglandin E1 bei fortgeschrittener arterieller Verschlusskrankheit-Ergebnisse einer multizentrischen Studie. In: Prostaglandin E1. Wirkungen und Therapeutische Wirksamkeit. Edited by H. Heidrich, H. Böhme and W. Rogatti. New York: Springer-Verlag, pp. 124-132, 1988.
201. Virag, R., Frydman, D., Legman, M. and Virag, H.: Intracavernous injection of papaverine as a diagnostic and therapeutic method in erectile failure. Angiology, 35: 79, 1984.
202. Puppo, P., de Rose, A. F. and Pittaluga, P.: Office and home protocols for intracavernous injection: results in 101 cases. In: Proceedings of the Third World Meeting on Impotence, p. 170, 1988.
203. Lue, T. F. and Goldstein, I.: Introduction. In: The Role of Alprostadil in the Diagnosis and Treatment of Erectile Dysfunction. Edited by I. Goldstein and T. F. Lue. Princeton: Excerpta Medica, Inc., pp. 1-2, 1993.
204. 1. Med. Klin., 87: 123, 1992.
205. Brecht, T. and Ayaz, M.: Circulation parameters during intravenous and intra-arterial administration of increasing doses of prostaglandin E1 in healthy subjects. Klin. Wochenschr., 63: 1201, 1985.
206. Heidrich, H., Brodel, C., Meuche, C., Hellmann, M. and Ranft, J.: Kontrollierte Blutdrucklangzeitmessung unter intravenöser Prostaglandin E1-Infusion. Vasa, 20: 13, 1991.
207. Naeije, R. C., Mélot, C., Mols, P. and Hallemans, R.: Reduction in pulmonary hypertension by prostaglandin E1 in decompensated chronic obstructive pulmonary disease. Amer. Rev. Resp. Dis., 125: 1, 1982.
208. Feldman, R. L., Rose, B. and Verbust, K. M.: Hemodynamic and angiographic effects of prostaglandin E1 in coronary artery disease. Amer. J. Cardiol., 62: 698, 1988.
209. Ramanathan, J., Wilson, J. L., Ingram, L. A. and Mirvis, D. M.: Effect of PGE1 on transmyocardial distribution of coronary and collateral blood flow - absence of coronary steal. Clin. Res., 37: 29A, 1989.
210. Kelly, R. W., Quayle, A. J., Wallace, E. M., Wu, F. C. W., Hargraeve, T. B. and James, K.: Immunosuppression by prostaglandins found in human semen. In: Abstract Book, 7th International Conference on Prostaglandins and Related Compounds. May 28-June 1, 1990. Florence, Italy, p. 168, 1990.
211. Pollack, R., Dumble, L. and Moran, M.: The immunosuppressive properties of the prostaglandin E1 analogue Misoprostol and Enisoprost. In: Abstract Book, 7th International Conference on Prostaglandins and Related Compounds. May 28-June 1, 1990. Florence, Italy, p. 336, 1990.
212. Waymack, J. P., Klimpel, G., Haithcoat, J., Rutan, R. L. and Herndon, D. N.: Effect of prostaglandin E on immune function in normal healthy volunteers. Surg., Gynec. & Obst., 175: 329, 1992.
213. Goodwin, J. S. and Clay, G. A.: Effect of chronic ingestion of a prostaglandin E analogue on immunologic function in healthy elderly subjects. Int. J. Immunopharmacol., 8: 867, 1986.
214. Ellis, L. M., Copeland, E. M., III, Bland, K. I. and Sitren, H. S.: Inhibition of tumor growth and metastasis by chronic intravenous infusion of prostaglandin E1. Ann. Surg., 212: 45, 1990.
215. Foultier, M. T., Yactayo, S., Patrice, T. and Houillon, G.: Endothelial or cancer cells growth regulation by PGE1 analogue Misoprostol. In: Abstract Book, 7th International Conference on Prostaglandins and Related Compounds. May 28-June 1, 1990. Florence, Italy, p. 297, 1990.
216. Phipps, R. P., Stein, S. H. and Roper, R. L.: A new view of prostaglandin E regulation of the immune response. Immunol. Today, 12: 349, 1991.
217. Porst, H.: Prostaglandin E1 and the nitric oxide donor linsidomine for erectile failure: a diagnostic comparative study of 40 patients. J. Urol., part 2, 149: 1280, 1993.
218. Stief, C. G., Holmquist, F., Allhoff, E. P., Andersson, K. E. and Jonas, U.: Preliminary report on the effect of the nitric oxide donor SIN-1 on human cavernous tissue in vivo. World J. Urol., 9: 237, 1991.
219. Knispel, H. H., Wegner, A. E. H. and Miller, K.: The role of linsidomine (SIN-1) in diagnosis and treatment of erectile dysfunction. Int. J. Impotence Res., suppl. 1, 6: D156, 1994.